Patrick Liu, M.D., Ph.D., is Vice President of Global Biologics R&D and Head of Biologics, Assays and Technology at Teva Pharmaceuticals. Dr. Liu leads a global team with responsibilities from late stage research, through IND, clinical trials and marketing registration, with focus on product biological characterization, nonclinical and clinical PK/PD, biomarker evaluation and immunogenicity assessment for both innovative biologics and biosimilars development.
Prior to joining Teva, Dr. Liu held positions as a Director at Tanox and then Genentech with an increasing leadership role in bioanalytical sciences for the development and commercialization of a variety of new biologics across the therapeutic areas of oncology, hematology, immunology, allergy, respiratory and infectious diseases. He has contributed to the success of developing many blockbuster medicines including Avastin, Herceptin, Perjta, Lucentis, Xolair, Lonqex, Copaxone, Granix and most recently Cinqair. Dr. Liu has practiced medicine, specializing in Endocrinology and also holds a Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical College and Chinese Academy of Medical Sciences.